Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Net Income (2018 - 2025)

Historic Net Income for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$708991.0.

  • BioNexus Gene Lab's Net Income rose 4730.14% to -$708991.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 16676.32%. This contributed to the annual value of -$1.6 million for FY2024, which is 3846.25% up from last year.
  • According to the latest figures from Q3 2025, BioNexus Gene Lab's Net Income is -$708991.0, which was up 4730.14% from -$616172.0 recorded in Q2 2025.
  • BioNexus Gene Lab's Net Income's 5-year high stood at $671809.0 during Q4 2021, with a 5-year trough of -$2.6 million in Q3 2023.
  • Its 5-year average for Net Income is -$263310.9, with a median of -$63621.0 in 2024.
  • The largest annual percentage gain for BioNexus Gene Lab's Net Income in the last 5 years was 77148.37% (2023), contrasted with its biggest fall of 327100.17% (2023).
  • BioNexus Gene Lab's Net Income (Quarter) stood at $671809.0 in 2021, then tumbled by 107.79% to -$52349.0 in 2022, then surged by 771.48% to $351515.0 in 2023, then plummeted by 197.1% to -$341331.0 in 2024, then plummeted by 107.71% to -$708991.0 in 2025.
  • Its Net Income stands at -$708991.0 for Q3 2025, versus -$616172.0 for Q2 2025 and -$623327.0 for Q1 2025.